what does the fda approval of sarclisa® (isatuximab) mean for myeloma patients?
Published 4 years ago • 1.7K plays • Length 3:07Download video MP4
Download video MP3
Similar videos
-
4:36
what is isatuximab? and how does it compare with daratumumab?
-
8:00
all about sarclisa (isatuximab) #myeloma
-
0:45
fda approval of teclistamab for r/r multiple myeloma and the value of immunotherapies
-
3:30
what does it mean to be refractory to revlimid®? what other treatment options are available?
-
59:52
best of 2021 asco & eha webinar
-
21:39
frontline therapy for multiple myeloma - pfs webinar 031420
-
30:14
when myeloma comes back
-
1:18
the talisman study: prophylactic treatment for talquetamab-related oral toxicity in myeloma
-
3:56
what supplements, if any, should a myeloma patient take?
-
1:20
dr. yee on the utility of isatuximab in combination therapy for relapsed/refractory myeloma
-
18:32
what all myeloma patients need to know in 2021: from myeloma 101 to vaccines and variants
-
4:29
is it safe for myeloma patients in remission to stop ongoing maintenance therapy?
-
3:09
what is the current covid-19 status for myeloma patients?
-
10:56
stockholm 2018: what is the role of mass spectrometry in multiple myeloma
-
4:34
what is ide-cel and how can it benefit myeloma patients?
-
2:52
do fractures resulting from a fall indicate myeloma progression?
-
2:59
what is multiple myeloma?
-
3:36
how do multiple myeloma experts define cure?
-
1:00:05
myeloma month: navigating cancer series workshop